Transcatheter aortic valve implantation (TAVI) for aortic stenosis is becoming an appealing alternative to surgical aortic valve replacement in high-risk patients and to medical therapy for inoperable ones. Several new-generation TAVI devices have been recently introduced, but comparative analyses are lacking. We aimed to compare 1-month outcomes associated with such five leading new-generation TAVI devices exploiting data collected in the prospective observational RISPEVA (Registro Italiano GISE sull'impianto di Valvola Aortica Percutanea) Study.
Giordano A, Corcione N, Ferraro P, Morello A, Conte S, Testa L, Bedogni F, Iadanza A, Berti S, Regazzoli D, Romagnoli E, Trani C, Burzotta F, Pepe M, Frati G, Biondi-Zoccai G; Registro Italiano GISE sull’impianto di Valvola Aortica Percutanea (RISPEVA) Study Investigators. Tremoli E among collaborators. Comparative one-month safety and effectiveness of five leading new-generation devices for transcatheter aortic valve implantation. Sci Rep 2019 Nov 19;9(1):17098. doi: 10.1038/s41598-019-53081-w